Dental Products Advisory Committee
This article was originally published in The Gray Sheet
Meeting Feb. 11-12 in Bethesda, Maryland. On Feb. 11, the committee is scheduled to discuss guidance documents for temporomandibular joint implants and periodontal test kits. Time permitting, the panel may also make classification recommendations for TMJ implants, root apex locators, electrical anesthesia devices and bone-filling and augmentation devices. The Feb. 12 session is slated for a discussion of dental amalgam issues and review of a marketing application for a root canal filling material. Contact person is Carolyn Tylenda (301) 427-1090.
You may also be interested in...
Office of New Drugs Director Peter Stein said in an interview that a large amount of coronavirus-related work is arriving at the FDA, but so far staff are keeping up.
Akero’s FGF21 analog yields 63%-72% relative hepatic fat reduction in Phase IIa study; the company awaits biopsy data hoping to see a fibrotic benefit. Also, Genfit says COVID-19 pandemic should not significantly delay its Phase III NASH readout.
US Vice President Mike Pence and Medicare administrator Seema Verma want academic and university hospital laboratories to send their de-identified COVID-19 test data results, daily, to the Department of Health and Human Services. Commercial and private labs are exempt from the request, as they already share their coronavirus test results with the government.